Table 2.
Factors associated with the risk of intestinal ulcers flare-ups
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Male sex | 2.28 (0.46–11.25) | 0.441 | – | – |
| Age at the diagnosis of BS > 35 years | 2.64 (0.54–13.03) | 0.262 | – | – |
| Onset of BS (< 7 years) | 1.31 (0.31–5.58) | 1.000 | – | – |
| Intestinal symptoms | 4.72 (0.59–37.90) | 0.132 | 5.14 (0.58–45.12) | 0.140 |
| Endoscopic characteristics | ||||
| Location (ileocecal and colorectum) | 0.59 (0.08–4.67) | 1.000 | – | – |
| Number, ≥ 3 | 0.16 (0.02–1.31) | 0.060 | 0.15 (0.02–1.29) | 0.084 |
| Size, > 1 cm | 3.07 (0.73–12.96) | 0.196 | – | – |
| Lab parameters | ||||
| WBC > 6.4, × 109/L | 0.76 (0.18–3.25) | 1.000 | – | – |
| Hb < 123, g/L | 0.79 (0.19–3.38) | 1.000 | – | – |
| ESR > 24, mm/h | 1.36 (0.32–5.78) | 0.716 | – | – |
| CRP > 10, mg/L | 2.55 (0.52–12.57) | 0.271 | – | – |
| Positive FOBT+ | 1.50 (0.31–7.22) | 0.617 | – | – |
| Positive T-SPOT | 0.79 (0.10–6.18) | 1.000 | – | – |
| HBV-DNA | 6.87 (1.66–28.36) | 0.287 | – | – |
| Treatment | ||||
| Biologics | 1.83 (0.37–9.00) | 0.697 | – | – |
| IFX therapy# | 1.41 (0.33–6.00) | 0.711 | – | – |
| Poor compliance | 0.38 (0.05–3.06) | 0.673 | – | – |
+FOBT: fecal occult blood test
#IFX therapy was administrated at 0,2, and 6 weeks (intravenous), and then maintained with the same dosage of IFX every 8 weeks